ACXP RSI Chart
Last 7 days
4.0%
Last 30 days
-3.2%
Last 90 days
-34.2%
Trailing 12 Months
-23.9%
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Jan 19, 2024 | sailer carl | acquired | 70,066 | 3.55 | 19,737 | - |
Jan 03, 2024 | deluccia robert j | acquired | 70,066 | 3.55 | 19,737 | - |
Jan 03, 2024 | luci david p | acquired | 70,066 | 3.55 | 19,737 | president and ceo |
Dec 22, 2023 | deluccia robert j | gifted | - | - | -30,000 | - |
Dec 12, 2023 | deluccia robert j | gifted | - | - | -40,000 | - |
Jul 27, 2022 | deluccia robert j | bought | 75,000 | 3.8 | 19,737 | - |
Jul 27, 2022 | luci david p | bought | 75,000 | 3.8 | 19,737 | president and ceo |
Jul 27, 2022 | sailer carl | bought | 75,000 | 3.8 | 19,737 | - |
Dec 02, 2021 | deluccia robert j | gifted | - | - | -40,000 | - |
Nov 23, 2021 | sailer carl | bought | 24,979 | 4.84 | 5,161 | - |
Which funds bought or sold ACXP recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
May 01, 2024 | CONCOURSE FINANCIAL GROUP SECURITIES, INC. | sold off | - | - | - | -% |
Apr 30, 2024 | GPS Wealth Strategies Group, LLC | unchanged | - | -690 | 1,225 | -% |
Apr 30, 2024 | Patriot Financial Group Insurance Agency, LLC | new | - | 25,443 | 25,443 | -% |
Apr 25, 2024 | SIMPLEX TRADING, LLC | new | - | 26,000 | 26,000 | -% |
Apr 24, 2024 | Cambridge Investment Research Advisors, Inc. | new | - | 25,000 | 25,000 | -% |
Apr 22, 2024 | Prospect Financial Services LLC | added | 6.94 | -308,742 | 668,483 | 0.55% |
Apr 19, 2024 | Cutler Group LLC / CA | reduced | -47.83 | -6,000 | 2,000 | -% |
Apr 05, 2024 | NBC SECURITIES, INC. | new | - | 34,000 | 34,000 | -% |
Mar 11, 2024 | VANGUARD GROUP INC | added | 235 | 1,374,600 | 1,556,460 | -% |
Feb 14, 2024 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | new | - | 205,108 | 205,108 | -% |
Unveiling Acurx Pharmaceuticals, Inc.'s Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to Acurx Pharmaceuticals, Inc.)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
MRNA | 48.1B | 6.8B | -8.06 | 7.03 | ||||
HILS | 22.4B | 152.6K | -2.4K | 146.8K | ||||
ALNY | 19.0B | 2.0B | -57.25 | 9.49 | ||||
BMRN | 15.9B | 2.5B | 77.41 | 6.43 | ||||
INCY | 11.9B | 3.8B | 15.99 | 3.16 | ||||
MID-CAP | ||||||||
APLS | 5.7B | 396.6M | -10.83 | 14.44 | ||||
BBIO | 5.2B | 107.9M | -9.5 | 48.09 | ||||
AXSM | 3.5B | 270.6M | -14.69 | 12.99 | ||||
ARWR | 3.0B | 240.7M | -10.07 | 12.18 | ||||
ACAD | 2.8B | 726.4M | -45.92 | 3.87 | ||||
SMALL-CAP | ||||||||
CPRX | 1.8B | 398.2M | 24.79 | 4.45 | ||||
NVAX | 659.2M | 983.7M | -1.21 | 0.67 | ||||
CRBP | 400.8M | 881.7K | -8.99 | 466.16 | ||||
INO | 280.7M | 4.9M | -2.08 | 57.68 | ||||
IBIO | 7.0M | 2.1M | -0.26 | 2.14 |
Acurx Pharmaceuticals, Inc. News
Balance Sheet | ||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2020Q4 |
Assets | -5.1% | 7,709 | 8,126 | 8,543 | 8,960 | 9,377 | 9,259 | 11,322 | 13,254 | 14,990 | 17,440 | 3,224 |
Current Assets | -100.0% | - | 7,158 | 9,236 | 7,385 | 9,377 | 9,209 | - | 13,254 | - | - | - |
Cash Equivalents | 6.0% | 7,474 | 7,052 | 9,146 | 7,179 | 9,112 | 9,092 | 11,083 | 12,959 | 14,459 | 17,096 | 3,175 |
Liabilities | -5.6% | 3,042 | 3,223 | 3,019 | 2,074 | 2,062 | 474 | 633 | 844 | 712 | 1,919 | 522 |
Current Liabilities | -5.6% | 3,042 | 3,223 | 3,019 | 2,074 | 2,062 | 474 | 633 | 844 | 712 | 1,919 | 473 |
Shareholder's Equity | 18.6% | 4,667 | 3,935 | 6,216 | 5,311 | 7,315 | 8,785 | 10,689 | 12,410 | 14,277 | 15,522 | 2,702 |
Retained Earnings | -10.6% | -53,218 | -48,104 | -44,989 | -41,544 | -38,641 | -31,838 | -29,218 | -26,548 | -23,921 | -19,279 | -13,800 |
Additional Paid-In Capital | 11.2% | 57,871 | 52,026 | 51,193 | 46,844 | 45,944 | 40,614 | 39,897 | 38,948 | 38,188 | 34,791 | - |
Shares Outstanding | 11.3% | 14,468 | 13,005 | 13,005 | 11,672 | 11,628 | 10,263 | 10,233 | 10,216 | 10,116 | 6,908 | 6,191 |
Float | - | - | - | 27,900 | - | - | 29,800 | - | - | - | 48,100 | - |
Cashflow (Quarterly) | ||||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 |
Cashflow From Operations | -100.5% | -4,197 | -2,093 | -1,576 | -1,932 | -1,495 | -2,180 | -1,990 | -1,876 | -1,500 | -2,636 | -329 | -547 | - | - | - |
Share Based Compensation | 0% | 833 | 833 | 806 | 733 | 697 | 697 | 717 | 761 | 673 | 2,071 | 2,220 | 192 | - | - | - |
Cashflow From Financing | - | 4,620 | - | - | - | -1* | - | - | - | - | - | - | - | - | - | - |
STATEMENTS OF OPERATIONS - USD ($) | 12 Months Ended | |
---|---|---|
Dec. 31, 2023 | Dec. 31, 2022 | |
OPERATING EXPENSES | ||
Research and Development | $ 6,043,597 | $ 4,754,271 |
General and Administrative | 8,534,171 | 7,338,505 |
TOTAL OPERATING EXPENSES | 14,577,768 | 12,092,776 |
NET LOSS | $ (14,577,768) | $ (12,092,776) |
LOSS PER SHARE | ||
Basic net loss per common share | $ (1.15) | $ (1.12) |
Diluted net loss per common share | $ (1.15) | $ (1.12) |
Weighted average common shares outstanding basic | 12,671,572 | 10,816,412 |
Weighted average common shares outstanding diluted | 12,671,572 | 10,816,412 |
BALANCE SHEETS - USD ($) | Dec. 31, 2023 | Dec. 31, 2022 |
---|---|---|
CURRENT ASSETS | ||
Cash | $ 7,474,188 | $ 9,111,751 |
Other Receivable | 129,159 | |
Prepaid Expenses | 105,776 | 264,955 |
TOTAL ASSETS | 7,709,123 | 9,376,706 |
CURRENT LIABILITIES | ||
Accounts Payable and Accrued Expenses | 3,042,438 | 2,061,685 |
TOTAL CURRENT LIABILITIES | 3,042,438 | 2,061,685 |
TOTAL LIABILITIES | 3,042,438 | 2,061,685 |
COMMITMENTS AND CONTINGENCIES | ||
SHAREHOLDERS' EQUITY | ||
Common Stock; $.001 par value, 200,000,000 shares authorized, 14,468,229 and 11,627,609 shares issued and outstanding at December 31, 2023 and December 31, 2022, respectively | 14,468 | 11,628 |
Additional Paid-In Capital | 57,871,070 | 45,944,478 |
Accumulated Deficit | (53,218,853) | (38,641,085) |
TOTAL SHAREHOLDERS' EQUITY | 4,666,685 | 7,315,021 |
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY | $ 7,709,123 | $ 9,376,706 |